Karuna Therapeutics, Inc. KRTX
We take great care to ensure that the data presented and summarized in this overview for Karuna Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding KRTX
View all-
Pictet Asset Management Sa Geneva 73, V8213KShares$00.06% of portfolio
-
Tekla Capital Management LLC58.6KShares$00.5% of portfolio
-
International Biotechnology Trust PLC London, X030.5KShares$01.75% of portfolio
-
Ea Series Trust Havertown, PA12.8KShares$00.1% of portfolio
-
Brinker Capital Investments, LLC6.1KShares$00.02% of portfolio
-
Virginia Retirement Systems Et Al Richmond, VA5KShares$00.01% of portfolio
-
Kellner Capital, LLC New York, NY4.1KShares$02.34% of portfolio
-
Exane Derivatives740Shares$00.06% of portfolio
-
Four Thought Financial, LLC Venice, FL143Shares$00.0% of portfolio
-
Wipfli Financial Advisors Llc,56Shares$00.0% of portfolio
Latest Institutional Activity in KRTX
Top Purchases
Top Sells
About KRTX
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psychosis. The company also focuses on developing other muscarinic-targeted drug candidates. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Insider Transactions at KRTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 18
2024
|
Stephen K. Brannan Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
42,604
-92.39%
|
$14,059,320
$330.0 P/Share
|
|
Mar 18
2024
|
William P Kane Jr Chief Commercial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
13,828
-68.08%
|
$4,563,240
$330.0 P/Share
|
|
Mar 18
2024
|
William Meury President and CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
29,379
-67.6%
|
$9,695,070
$330.0 P/Share
|
|
Mar 18
2024
|
Jason Parker Brown Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
21,167
-83.09%
|
$6,985,110
$330.0 P/Share
|
|
Mar 18
2024
|
Christopher J Coughlin |
SELL
Sale (or disposition) back to the issuer
|
Direct |
990
-100.0%
|
$326,700
$330.0 P/Share
|
|
Mar 18
2024
|
Steven M Paul |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
140,367
-100.0%
|
$46,321,110
$330.0 P/Share
|
|
Mar 18
2024
|
Steven M Paul |
SELL
Sale (or disposition) back to the issuer
|
Direct |
10,596
-59.65%
|
$3,496,680
$330.0 P/Share
|
|
Mar 18
2024
|
Andrew Craig Miller President of R&D |
SELL
Sale (or disposition) back to the issuer
|
Direct |
23,389
-79.88%
|
$7,718,370
$330.0 P/Share
|
|
Mar 18
2024
|
James Healy |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
1,381,149
-100.0%
|
$455,779,170
$330.0 P/Share
|
|
Mar 18
2024
|
James Healy |
SELL
Sale (or disposition) back to the issuer
|
Direct |
33,490
-98.52%
|
$11,051,700
$330.0 P/Share
|
|
Mar 18
2024
|
Jeffrey M Jonas |
SELL
Sale (or disposition) back to the issuer
|
Direct |
990
-100.0%
|
$326,700
$330.0 P/Share
|
|
Mar 18
2024
|
Laurie J Olson |
SELL
Sale (or disposition) back to the issuer
|
Direct |
990
-100.0%
|
$326,700
$330.0 P/Share
|
|
Mar 18
2024
|
Atul Pande |
SELL
Sale (or disposition) back to the issuer
|
Direct |
990
-100.0%
|
$326,700
$330.0 P/Share
|
|
Mar 18
2024
|
Denice Torres |
SELL
Sale (or disposition) back to the issuer
|
Direct |
990
-100.0%
|
$326,700
$330.0 P/Share
|
|
Mar 18
2024
|
David E. Wheadon |
SELL
Sale (or disposition) back to the issuer
|
Direct |
990
-100.0%
|
$326,700
$330.0 P/Share
|
|
Mar 08
2024
|
Stephen K. Brannan Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-5.26%
|
$1,590,000
$318.64 P/Share
|
|
Mar 08
2024
|
Stephen K. Brannan Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+5.24%
|
$622,500
$83.02 P/Share
|
|
Mar 04
2024
|
Steven M Paul |
BUY
Bona fide gift
|
Indirect |
30,304
+50.0%
|
-
|
|
Mar 04
2024
|
Steven M Paul |
SELL
Bona fide gift
|
Indirect |
30,304
-92.76%
|
-
|
|
Mar 01
2024
|
Steven M Paul |
BUY
Bona fide gift
|
Indirect |
60,608
+49.06%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 76.5K shares |
|---|---|
| Bona fide gift | 90.9K shares |
| Other acquisition or disposition | 47.4K shares |
| Sale (or disposition) back to the issuer | 1.7M shares |
|---|---|
| Payment of exercise price or tax liability | 15.7K shares |
| Open market or private sale | 35K shares |
| Bona fide gift | 90.9K shares |